Safety and Efficacy of Apixaban vs Warfarin in Patients With Stage 4 and 5 Chronic Kidney Disease: A Systematic Review

Warfarin has been an anticoagulant of choice in patients with advanced Chronic Kidney Diseases (CKD) at stages 4 and 5 for decades, but with the advent of Novel Oral Anticoagulants (NOACs), there has been a sharp rise in their prescriptions. Among all NOACS, apixaban is the least reliant on kidney f...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2022-10, Vol.14 (10), p.e30230-e30230
Main Authors: Fatima, Hameeda, Nwankwo, Ijeoma, Anam, Mahvish, Maharjan, Shrinkhala, Amjad, Zainab, Abaza, Abdelrahman, Vasavada, Advait M, Sadhu, Akhil, Valencia, Carla, Khan, Safeera
Format: Article
Language:English
Subjects:
Anticoagulants
Bias
Bibliographic literature
Cardiac arrhythmia
Cardiology
Clinical trials
Cohort analysis
Creatinine
FDA approval
Hemodialysis
Internal Medicine
Kidney diseases
Nephrology
Stroke
Systematic review
Thromboembolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Warfarin has been an anticoagulant of choice in patients with advanced Chronic Kidney Diseases (CKD) at stages 4 and 5 for decades, but with the advent of Novel Oral Anticoagulants (NOACs), there has been a sharp rise in their prescriptions. Among all NOACS, apixaban is the least reliant on kidney function and is a very popular choice for this patient population. However, being utilized extensively, most of the landmark trials evaluating the safety and efficacy of apixaban excluded patients with Creatinine Clearance (CrCl)
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.30230